SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
leader crossed forbidden line, leadership vector concept, finish line and winner
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
Obesity
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Man walking on a boardwalk in the fog
Depression
Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression
Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called COMP360’s efficacy “more than good enough” for registrational purposes.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
©Vertex Pharmaceuticals Incorporated. All Rights Reserved.
Diabetes
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target population and Vertex’s execution hang over the cell therapy’s commercial potential.
June 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Rare diseases
IRA Leaves Orphan Drugs Stranded Even as Regulators Promise Progress
The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from sufficient to maintain momentum in the rare disease space.
June 23, 2025
 · 
7 min read
 · 
Heather McKenzie
Refusal to contact. Barrier to negotiations. Division, separation. Protagonist, antagonist, minions. Mediation and conflict resolution.
Vaccines
Experts Say Axed ACIP Members’ Conflicts of Interest Are ‘a Red Herring’
In advance of this week’s CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming problematic industry ties within the previous group. Experts say ACIP had long navigated COIs appropriately and that the new appointees risk the apolitical nature of membership.
June 23, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
USA, Scenic San Diego downtown financial district city skyline and skyscrapers.
Job Trends
8 Companies Hiring in San Diego
Looking for a biopharma job in San Diego? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
June 20, 2025
 · 
1 min read
 · 
Angela Gabriel
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
Zealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for More
Analysts at William Blair say dapiglutide’s 11.6% weight reduction at 28 weeks could still be better, given that Zealand’s study predominantly included men and enrolled patients with lower BMI at baseline.
June 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Rare diseases
Cycle Wins First FDA Nod for Ultra-Rare Genetic Disease
Harliku is the only FDA-approved drug for alkaptonuria, a rare condition characterized by skin discoloration, arthritis and heightened risks of heart failure and stroke.
June 20, 2025
 · 
1 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS